Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer See more here
Read More
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023 - ENB-003 in combination with KEYTRUDA (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC) - Encouraging results support further development…
Read More
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023 ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint - The ENB-003 in combination with KEYTRUDA® (pembrolizumab)…
Read More
ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint See more here
Read More
ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint See more here
Read More
ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab ENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint See more here
Read More
ENB Therapeutics Announces Successful Completion of the First Dosing Cohort in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab ENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint See more here
Read More
ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA(R) (pembrolizumab) for Advanced Solid Tumors See more here
Read More
ENB Therapeutics Closes Series A Round of Funding Remiges led the Series A round of Financing See more here
Read More